A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology—A Pilot Cohort Study

A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology—A Pilot Cohort Study

Background: Thyroid ultrasound (US), fine needle aspiration biopsy (FNAB), and molecular testing have been widely used to stratify the risk of malignancy in thyroid nodules. The goal of this study was to investigate a novel diagnostic approach for cytologically indeterminate thyroid nodules (ITN) ba...

Full description

Bibliographic Details
Main Authors:	Cristiane J. Gomes-Lima, Sungyoung Auh, Shilpa Thakur, Marina Zemskova, Craig Cochran, Roxanne Merkel, Armando C. Filie, Mark Raffeld, Snehal B. Patel, Liqiang Xi, Leonard Wartofsky, Kenneth D. Burman, Joanna Klubo-Gwiezdzinska
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-02-01
Series:	Frontiers in Endocrinology
Subjects:	thyroid nodule thyroid ultrasound fine needle aspiration biopsy indeterminate cytology molecular testing
Online Access:	https://www.frontiersin.org/article/10.3389/fendo.2020.00053/full

Similar Items

Indeterminate thyroid nodules in the era of molecular genomics
by: Sarika N. Rao, et al.
Published: (2020-09-01)

Uni- and Multivariate Analyses of Cancer Risk in Cytologically Indeterminate Thyroid Nodules: A Single-Center Experience
by: Enrico Battistella, et al.
Published: (2024-02-01)

Ultrasound elastography in the diagnostic evaluation of indeterminate thyroid nodule
by: Sherif Fathy Abdelrahman, et al.
Published: (2015-09-01)

Role of Inflammatory Biomarkers (NLR, LMR, PLR) in the Prognostication of Malignancy in Indeterminate Thyroid Nodules
by: Claudio Gambardella, et al.
Published: (2023-03-01)

Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules
by: Navjit Dharampal, et al.
Published: (2022-12-01)

ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology
by: Thayse Lozovoy Madsen Barbosa, et al.
Published: (2019-10-01)

Reporting Thyroid Cytology in a Globalized World
by: Cristina Pizzimenti, et al.
Published: (2021-09-01)

Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification
by: Yuanyuan Zhou, et al.
Published: (2023-09-01)

Surgical Management of Indeterminate Thyroid Nodules across Different World Regions: Results from a Retrospective Multicentric (the MAIN-NODE) Study
by: Gian Luigi Canu, et al.
Published: (2023-08-01)

The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology
by: Marco Capezzone, et al.
Published: (2021-02-01)

Risk of Complications in Patients Undergoing Completion Thyroidectomy after Hemithyroidectomy for Thyroid Nodule with Indeterminate Cytology: An Italian Multicentre Retrospective Study
by: Gian Luigi Canu, et al.
Published: (2022-05-01)

PAPPA Expression in Indeterminate Thyroid Nodules as Screening Test to Select Patients for Molecular Testing
by: Carlotta Marzocchi, et al.
Published: (2022-04-01)

Comparison of S-Detect and thyroid imaging reporting and data system classifications in the diagnosis of cytologically indeterminate thyroid nodules
by: Ling Zhou, et al.
Published: (2023-01-01)

Can current molecular tests help in the diagnosis of indeterminate thyroid nodule FNAB?
by: Carolina Ferraz

Approaching indeterminate thyroid nodules in the absence of molecular markers: “The BETH-TR score”
by: Sushma Mehta, et al.
Published: (2020-01-01)

Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules
by: Elizabeth J de Koster, et al.
Published: (2022-07-01)

An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules
by: Silvia Taccogna, et al.
Published: (2022-12-01)

Inter-Reader Agreement of ATA Sonographic Risk in Thyroid Nodules with Bethesda Category III Indeterminate Cytology
by: Maria I. Linares Valderrama, et al.
Published: (2021-04-01)

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III)
by: Shilpa Thakur, et al.
Published: (2019-09-01)

Evaluation of the Italian Cytological Reporting System and Comparison with Histopathology with Respect to Indeterminate Thyroid Lesions
by: Anita P Javalgi, et al.
Published: (2021-04-01)

May 25-31, International thyroid awareness week & May 25, world thyroid day, 2022: Indetermination of indeterminate cytology, aus/flus, fn, susp, in thyroidology?
by: Sengul Ilker, et al.
Published: (2022-09-01)

Temporal Evolution and Prognostic Role of Indeterminate Response Sub-Groups in Patients with Differentiated Thyroid Cancer after Initial Therapy with Radioiodine
by: Domenico Albano, et al.
Published: (2023-02-01)

Histopathology of telomerase reverse transcriptase promoter (TERT) mutated indeterminate thyroid nodules
by: Jessica O. Pinto, et al.
Published: (2024-03-01)

Radiofrequency Ablation of Indeterminate Thyroid Nodules: The First North American Comparative Analysis
by: Peter P. Issa, et al.
Published: (2022-09-01)

Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
by: Gustavo Cancela e Penna, et al.
Published: (2021-09-01)

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool
by: Xuhuizi Guan, et al.
Published: (2023-02-01)

Stratifying Indeterminate Cytology Thyroid Nodules by Combining Thyroid Imaging Reporting and Data Systems (TI-RADS) and The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC)
by: Steve Marlo Cambe, et al.
Published: (2023-11-01)

Molecular Tests for Risk-Stratifying Cytologically Indeterminate Thyroid Nodules: An Overview of Commercially Available Testing Platforms in the United States
by: Michiya Nishino, et al.
Published: (2021-05-01)

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit
by: Simona Censi, et al.
Published: (2017-10-01)

Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China
by: Yuntao Song, et al.
Published: (2020-11-01)

Cancer Rate of the Indeterminate Lesions at Low or High Risk According to Italian System for Reporting of Thyroid FNA
by: Stefano Valabrega, et al.
Published: (2018-07-01)

The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodine—A cohort study
by: Hongxiu Luo, et al.
Published: (2022-09-01)

Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?
by: Cristiane Gomes-Lima, et al.
Published: (2019-12-01)

Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study
by: Emad Kandil, et al.
Published: (2023-03-01)

The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology
by: Muhammed Erkam Sencar, et al.
Published: (2022-02-01)

Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy
by: Chunfang Hu, et al.
Published: (2022-04-01)

Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer
by: Athanasios Bikas, et al.
Published: (2020-09-01)

Pilot Study on the Use of Untargeted Metabolomic Fingerprinting of Liquid-Cytology Fluids as a Diagnostic Tool of Malignancy for Thyroid Nodules
by: Grégoire D’Andréa, et al.
Published: (2023-06-01)

Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models
by: Joanna Klubo-Gwiezdzinska, et al.
Published: (2017-09-01)

Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
by: Guochao Ye, et al.
Published: (2023-05-01)